Crinetics Pharmaceuticals Inc. has described drug conjugates consisting of a non-peptide moiety targeting G protein-coupled receptors (GPCRs) covalently linked to a chemotherapeutic moiety through a linker reported to be useful for the diagnosis and treatment of cancer.
While Alzheimer’s disease is known for involving amyloid-b plaques and neurofibrillary tangles, it also involves metabolic dysfunction, further research into which could help scientists understand how the disease occurs and how it can be treated.
Bayosthiti AI Pvt Ltd. aims to make RNA sequencing and AI-based preventive health care affordable and accessible for the Indian market, leveraging intellectual property from its parent company, Biostate AI Inc.
Peptidream Inc. has announced a new radiopharmaceutical candidate targeting cadherin-3 (CDH3) for the diagnosis and treatment of head and neck squamous cell carcinoma.
Cornell University and The General Hospital Corp. (Massachusetts General Hospital) have synthesized conjugates comprising a targeting moiety covalently linked to a radiolabeled metal chelator through a linker acting as positron emission tomography (PET) or single-photon emission computerized tomography (SPECT) imaging agents reported to be useful for diagnosis and treatment of cancer.
SK Biopharmaceuticals Co. Ltd. has signed a license agreement with the Wisconsin Alumni Research Foundation (WARF) to acquire rights to WARF’s WT-7695, a preclinical-stage radiopharmaceutical therapy candidate developed in collaboration with the University of Wisconsin-Madison.
South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.
South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes. Detailed in Cell Host & Microbe on Nov. 12, 2025, the database is expected to serve as a universal platform for academia and enable “precision microbiome medicine” for the industry, Lee told BioWorld.
RSS
